Literature DB >> 26517709

Psychometric modeling of abuse and dependence symptoms across six illicit substances indicates novel dimensions of misuse.

Shaunna L Clark1, Nathan A Gillespie2, Daniel E Adkins3, Kenneth S Kendler4, Michael C Neale4.   

Abstract

AIMS: This study explored the factor structure of DSM III-R/IV symptoms for substance abuse and dependence across six illicit substance categories in a population-based sample of males.
METHOD: DSM III-R/IV drug abuse and dependence symptoms for cannabis, sedatives, stimulants, cocaine, opioids and hallucinogens from 4179 males born 1940-1970 from the population-based Virginia Adult Twin Study of Psychiatric and Substance Use Disorders were analyzed. Confirmatory factor analyses tested specific hypotheses regarding the latent structure of substance misuse for a comprehensive battery of 13 misuse symptoms measured across six illicit substance categories (78 items).
RESULTS: Among the models fit, the latent structure of substance misuse was best represented by a combination of substance-specific factors and misuse symptom-specific factors. We found no support for a general liability factor to illicit substance misuse.
CONCLUSIONS: Results indicate that liability to misuse illicit substances is drug class specific, with little evidence for a general liability factor. Additionally, unique dimensions capturing propensity toward specific misuse symptoms (e.g., tolerance, withdrawal) across substances were identified. While this finding requires independent replication, the possibility of symptom-specific misuse factors, present in multiple substances, raises the prospect of genetic, neurobiological and behavioral predispositions toward distinct, narrowly defined features of drug abuse and dependence.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cannabis; Cocaine; DSM; Dependence; Factor analysis; Opioids

Mesh:

Substances:

Year:  2015        PMID: 26517709      PMCID: PMC4679450          DOI: 10.1016/j.addbeh.2015.10.015

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  35 in total

Review 1.  The Harvard Twin Study of Substance Abuse: what we have learned.

Authors:  M T Tsuang; J L Bar; R M Harley; M J Lyons
Journal:  Harv Rev Psychiatry       Date:  2001 Nov-Dec       Impact factor: 3.732

2.  Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins.

Authors:  Kenneth S Kendler; Kristen C Jacobson; Carol A Prescott; Michael C Neale
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

Review 3.  A review of the published literature into cannabis withdrawal symptoms in human users.

Authors:  Neil T Smith
Journal:  Addiction       Date:  2002-06       Impact factor: 6.526

4.  The structure of cannabis dependence in the community.

Authors:  Maree Teesson; Michael Lynskey; Barry Manor; Andrew Baillie
Journal:  Drug Alcohol Depend       Date:  2002-12-01       Impact factor: 4.492

5.  Cannabis and other illicit drugs: comorbid use and abuse/dependence in males and females.

Authors:  Arpana Agrawal; Michael C Neale; Carol A Prescott; Kenneth S Kendler
Journal:  Behav Genet       Date:  2004-05       Impact factor: 2.805

6.  An application of item response theory analysis to alcohol, cannabis, and cocaine criteria in DSM-IV.

Authors:  James W Langenbucher; Erich Labouvie; Christopher S Martin; Pilar M Sanjuan; Lawrence Bavly; Levent Kirisci; Tammy Chung
Journal:  J Abnorm Psychol       Date:  2004-02

7.  Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing.

Authors:  W Swift; W Hall; M Teesson
Journal:  Drug Alcohol Depend       Date:  2001-07-01       Impact factor: 4.492

Review 8.  DSM-5 criteria for substance use disorders: recommendations and rationale.

Authors:  Deborah S Hasin; Charles P O'Brien; Marc Auriacombe; Guilherme Borges; Kathleen Bucholz; Alan Budney; Wilson M Compton; Thomas Crowley; Walter Ling; Nancy M Petry; Marc Schuckit; Bridget F Grant
Journal:  Am J Psychiatry       Date:  2013-08       Impact factor: 18.112

9.  Factor structures for DSM-IV substance disorder criteria endorsed by alcohol, cannabis, cocaine and opiate users: results from the WHO reliability and validity study.

Authors:  C B Nelson; J Rehm; T B Ustün; B Grant; S Chatterji
Journal:  Addiction       Date:  1999-06       Impact factor: 6.526

Review 10.  Rave drugs: pharmacological considerations.

Authors:  Mary Klein; Frances Kramer
Journal:  AANA J       Date:  2004-02
View more
  5 in total

Review 1.  Impulsivities and addictions: a multidimensional integrative framework informing assessment and interventions for substance use disorders.

Authors:  Jasmin Vassileva; Patricia J Conrod
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-18       Impact factor: 6.237

2.  Machine-learning identifies substance-specific behavioral markers for opiate and stimulant dependence.

Authors:  Woo-Young Ahn; Jasmin Vassileva
Journal:  Drug Alcohol Depend       Date:  2016-02-15       Impact factor: 4.492

3.  Item Response Theory Analysis to Assess Dimensionality of Substance Use Disorder Abuse and Dependence Symptoms.

Authors:  Levent Kirisci; Ralph E Tarter; Maureen Reynolds; Michael M Vanyukov
Journal:  Int J Pers Cent Med       Date:  2016

4.  Associations of cannabis- and tobacco-related problem severity with reward and punishment sensitivity and impulsivity in adolescent daily cigarette smokers.

Authors:  Christopher J Hammond; Suchitra Krishnan-Sarin; Linda C Mayes; Marc N Potenza; Michael J Crowley
Journal:  Int J Ment Health Addict       Date:  2020-05-15       Impact factor: 3.836

5.  Validation of the Substance Use Risk Profile Scale (SURPS) With Bulgarian Substance Dependent Individuals.

Authors:  Elizabeth C Long; Svetla Milcheva; Elena Psederska; Georgi Vasilev; Kiril Bozgunov; Dimitar Nedelchev; Nathan A Gillespie; Jasmin Vassileva
Journal:  Front Psychol       Date:  2018-11-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.